The Yale Cancer Biology Institute (YCBI) connects scientists from across Yale to study the common underlying causes of cancer, wherever it appears. Traditional cancer research continues to focus on vital questions about the treatment and care of specific types of cancer. Complementing this work, today’s research also seeks to understand core cellular and molecular links across multiple cancers. The purpose of the Cancer Biology Institute is to study this core biology.
The YCBI was envisioned by founding Director Joseph Schlessinger, PhD, William H. Prusoff Professor of Pharmacology at Yale School of Medicine. Now joined by Mark A. Lemmon, PhD, the Alfred Gilman Professor and Chair of Pharmacology and the Institute’s Co-Director, the Institute will be created from the ground up, with 2-3 new laboratories coming on stream each year over the next 5 years.
Drs. Schlessinger and Lemmon are committed to building an institute for the long term and with a clear emphasis on making their research count for cancer. In concert with Yale Cancer Center, the Institute aims to become a driver of basic science through opportunities emerging from clinical research already at Yale.
Faculty Advisory Committee:
Mark Lemmon (Pharmacology), Co-Director
Joseph Schlessinger (Pharmacology), Co-Director
Marcus Bosenberg (Dermatology and Pathology)
Barbara Burtness (Medical Oncology)
David Calderwood (Pharmacology and Cell Biology)
Don Engelman (Molecular Biophysics and Biochemistry)
Roy Herbst (Pharmacology, Medicine/Medical Oncology)
Valerie Horsley (Molecular, Cellular and Developmental Biology and Dermatology)
Bill Jorgensen (Chemistry)
Kathryn Miller-Jensen (Biomedical Engineering)
David Stern (Pathology)
Scott Strobel (Ex officio) (Molecular Biophysics and Biochemistry)